Introduction
In early 2026, the U.S. fiscal landscape reflects major shifts from the One Big Beautiful Bill Act (OBBBA), signed in July 2025. This legislation extended and modified key provisions from the 2017 Tax Cuts and Jobs Act, while altering aspects of prior laws like the Inflation Reduction Act (IRA). Corporate tax expenditures—special deductions, credits, and exclusions that reduce tax liability—remain substantial, with projections showing significant flows in 2026.
Recent data indicates lobbying influenced these outcomes. Pharmaceuticals/Health Products led spending at over $341 million through September 2025, followed by other sectors adapting to new rules. The OBBBA delivered retroactive benefits, such as $67 billion in 2026 for research expenses already incurred, and revived full expensing for equipment and R&D. Clean energy subsidies faced scaling back, with some IRA credits modified or accelerated in phase-out, though others persist or shift. Overall tax expenditures favor business investment, with OBBBA adding hundreds of billions in deficits partly through these mechanisms. Subsidy disbursements under prior programs, like CHIPS Act grants, continue, with awards totaling billions allocated by early 2026.
These patterns show lobbying shaping direct subsidies (grants, awards) and tax breaks (expenditures like credits, deductions), often securing favorable terms amid policy changes.
Predictions for 2026
In 2026, industry lobbying will drive continued access to substantial subsidies and tax breaks, focusing on implementation of OBBBA provisions and preserving or expanding targeted incentives. The feedback loop—where influence secures financial advantages that fund further advocacy—strengthens.
Business tax breaks expand significantly. OBBBA reinstates 100% bonus depreciation permanently, allowing immediate full deduction of qualifying equipment costs. This benefits capital-intensive sectors like manufacturing and tech, reducing taxable income sharply in the year of purchase. Full expensing for domestic R&D costs resumes, including retroactive application for prior years, delivering large one-time benefits in 2026 filings. For example, corporations claim immediate deductions for research conducted since 2022, lowering effective tax rates and freeing cash for reinvestment or lobbying.
Direct subsidies flow through ongoing programs. CHIPS Act grants, awarding billions for semiconductor facilities, disburse based on milestones, with companies like Intel, TSMC, and Samsung receiving multi-billion packages. Lobbying by semiconductor interests ensured sustained funding despite reviews. Energy subsidies shift: OBBBA scales back some IRA clean energy credits, accelerating phase-outs for certain technologies, but preserves others like nuclear through 2031. Renewable advocates secure targeted extensions or bonuses for domestic content, directing flows to qualifying projects.
Pharma and health sectors benefit from OBBBA’s orphan drug expansions, exempting more treatments from Medicare negotiations, preserving higher reimbursement and revenue. This indirectly supports capital access via sustained profits. Finance and other industries gain from loosened interest deduction limits and permanent lower corporate rates, reducing tax burdens and enhancing after-tax returns.
Lobbying correlates with subsidy and break access. High-spending sectors position for favorable rulemaking on eligibility, reporting, and compliance. In 2026, expect $500+ billion in combined tax expenditures and subsidy disbursements influenced by advocacy, with OBBBA’s business provisions driving the bulk. Retroactive elements provide windfalls, while forward-looking incentives encourage investment aligned with policy goals.
Challenges and Risks
These mechanisms distort allocation. Benefits concentrate among large, well-lobbied firms, disadvantaging smaller competitors without influence resources. This reduces market entry and innovation from new players.
Fiscal strain grows: OBBBA adds hundreds of billions to deficits through tax cuts, with interest costs compounding. Over-reliance on targeted breaks creates complexity, raising compliance burdens and error risks.
Public perception suffers when subsidies appear tied to lobbying rather than broad merit, fostering cynicism. Competitive unfairness emerges if rules favor incumbents, potentially inflating costs or slowing transitions in key areas like energy.
Transparency remains uneven, as some indirect influence evades full disclosure, complicating evaluation of true drivers.
Opportunities
Targeted subsidies and breaks can spur growth. Bonus depreciation and R&D expensing encourage capital investment, boosting productivity and jobs in manufacturing. CHIPS disbursements strengthen domestic supply chains, enhancing security and economic resilience.
Energy incentives, even modified, support reliable transitions, aligning government and industry on priorities. When lobbying highlights national needs, it facilitates efficient allocation, accelerating development in strategic sectors.
Oversight tools, like public reporting on awards and expenditures, enable accountability, potentially refining programs for broader benefit.
Conclusion
In 2026, subsidies and tax breaks will flow heavily through OBBBA-shaped channels, with lobbying securing advantages in business expensing, R&D deductions, semiconductor grants, and select energy incentives. The system favors established players converting influence into financial gains, sustaining the loop in a post-OBBBA environment. While distortions and fiscal pressures pose risks, investment incentives offer growth potential. Most likely, patterns consolidate around large recipients, with incremental adjustments from transparency or budget constraints introducing modest balance over time.
